The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Southfield, MI

Birmingham, AL

Greensboro - Cardiology

Monroe, NC

Augusta, GA

Oxon Hill, MD

Media, PA

Tulsa, OK

East Syracuse, NY

Richmond Behavioral Associates

Ocala, FL

Winter Park, FL

Clearwater, FL

Tampa, FL

Beaumont, TX

Bradenton, FL

Waltham, MA

Methuen, MA

West Palm Beach, FL

Boca Raton, FL

Hollywood, FL

Pembroke Pines, FL

Miami Lakes, FL

Miami Springs, FL

Miami, FL

San Antonio, TX

Rapid City, SD

Denver, CO

Weslaco, TX

McAllen, TX

Basalt, CO

Albuquerque Neuroscience

Tucson, AZ

Redlands, CA

Riverside, CA

San Diego, CA

Covina, CA

Santa Ana, CA

Inspira Clinical Research

Irvine, CA

San Juan, PR

Huntington Beach, CA

Northridge, CA

Sacramento, CA

Bellevue, WA

Tacoma, WA

Tokyo, Japan

Lilly

Find clinical trials for Alzheimer's Disease in Louisville, KY

Related conditions:

Alzheimer's Disease trials near Louisville, KY, USA:

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)